IPO Heavyweight News Hits the Market!2025 Year 11 Month 6 The other day, the official website of the Shanghai Stock Exchange officially disclosed,Shenzhen Core Medical Technology Co., Ltd. (Abbreviation “Core Medical”) STAR Market IPO The application has been accepted.Core Medical's Impact on the STAR Market: A New Chapter for China's Innovative Medical Device Sector

Focus on Heart Failure Treatment, Core Medical Builds “Made in China” Artificial Heart Matrix

In the medical and health field, heart failure is a threat to human life and health. “Invisible Killer”. According to the "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024》Shows that in China 35 The prevalence of heart failure in people aged and above reaches 1.38%; According to data from Frost & Sullivan,2024 Nearly Global Heart Failure Patients in 6300 Hundreds of millions, the number of patients in China exceeds 1500 Tens of millions. Facing such a large patient population, Core Medical steps forward, focusing on the significant clinical needs of acute and chronic heart failure, becoming an innovative medical device enterprise dedicated to providing more comprehensive, more innovative, and higher-quality artificial heart products.

In this IPO, Core Medical plans to raise 1.217 billion yuan, which will be invested in the R&D project for advanced circulatory support products and the construction project of the artificial heart industrialization base., Marketing Network and Digital Construction Projects, Supplement Working Capital Projects.

Since its establishment, Core Medical has always adhered to original innovation and key core technology research, and pioneered the “Time-division and Zoning Dynamic Axial Full Magnetic Suspension Control Technology” And “Axial Flux Multi-Drive Motor Technology” Applied to the artificial heart field, building a complete product matrix covering both implantable and interventional devices, with comprehensive coverage. “Long-term→Short-term, Left Heart→Dual Heart, Pediatric→Adult” Clinical needs, bringing breakthroughs to the global artificial heart field “Made in China” A New Pattern.

As of the date of signing the prospectus, Core Medical has been deployed. 5 Implantable and 6 An interventional artificial heart product, with promising progress:1 Implantable products achieve commercialization,2 Several interventional products have entered the registration approval stage, and multiple products are in the clinical stage. More notably, the company has 3 One core product has been included in China's special review process for innovative medical devices, namely the implantable left ventricular assist system. Corheart®6Implantable Dual-Heart Assist System DuoCor®2 And Interventional Ventricular Assist System CorVad®4.0/6.0 The series, with the largest number of products in China's artificial heart field, demonstrates strong technical strength and product competitiveness.

From 2022 to the first half of 2025, Core Medical's operating revenue was 0 yuan, 16.5503 million yuan, 93.6884 million yuan, and 70.4776 million yuan respectively, with net losses of 178 million yuan, 170 million yuan, 132 million yuan, and 73 million yuan respectively.

Star Products Shine, Leading the Global Artificial Heart Technology Revolution

In Core Medical's product portfolio, several products have performed remarkably well, becoming leaders in the industry. “Star Product”. Among them,
Corheart®6 is the first commercialized third-generation fully magnetically levitated artificial heart developed by Core Medical. In April 2023, it was awarded the "Important Medical Achievement of China in the 21st Century" by the Chinese Academy of Medical Sciences. It is currently the smallest and lightest commercialized magnetically levitated implantable artificial heart globally. Measured by terminal implant volume, its market share in China exceeded 45% in 2024, ranking first in the industry. The magnetically levitated integrated dual-heart assist system DuoCor®2 has now entered the clinical stage, with the potential to address the global challenge of long-term treatment for biventricular heart failure. The interventional ventricular assist system CorVad®4.0/6.0 series is expected to be approved for marketing in the first quarter of 2026, potentially becoming China's first approved interventional artificial heart product.

Not only that, but Core Medical continues to make strides in product development, constantly breaking through technical bottlenecks. The magnetic levitation integrated implantable dual-heart assist systemDuoCor®2 Has entered the clinical stage, this product is expected to solve global “Congestive Heart Failure” Long-term Treatment Challenge Brings New Hope to Many Heart Failure Patients; Interventional Ventricular Assist System CorVad®4.0/6.0 The series is expected to be released in 2026 The first quarter of the year saw the approval for marketing, and if successfully implemented, it will become China's first approved intravascular artificial heart product, filling the market gap in this field in China.

Continuous Attention, Witnessing the Growth of Innovative Medical Enterprises

Core Medical's attempt to enter the STAR Market this time is based on the fifth set of standards of the STAR Market, which focuses more on supporting innovative enterprises with core technologies but are not yet profitable. This standard aligns closely with Core Medical’s development stage and technical attributes. As IPO The application has been accepted, and Core Medical is about to open a new chapter in the capital market. With the support of funding, it is expected to further increase R&D investment, accelerate product iteration, and expand its market share.